Medicaid programs will be on the front lines in the struggle to afford high-cost gene therapies and treatment developers should be mindful of how pricing decisions will play out in the states, warned Harvard Pilgrim Health Care chief medical officer Michael Sherman.
“I believe as we see more of these coming to market, we will see more pressure, not just with commercial payers but with state Medicaid plans, which are the canary in the coal mines because they have to operate within a fixed budget,” Sherman
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?